好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

SmartRehab: Enhancing Stroke Recovery through Automated Telerehabilitation
Cerebrovascular Disease and Interventional Neurology
P7 - Poster Session 7 (5:00 PM-6:00 PM)
14-011

We tested the SmartRehab efficacy, usability, and feasibility for stroke rehabilitation across seven countries.
Stroke is a major cause of disability worldwide. Timely and personalized rehabilitation is critical for recovery, yet current methods are limited by medical shortages, overwhelmed healthcare systems, and insurance constraints. Telerehabilitation has emerged as a promising solution to address these gaps. The SmartRehab app, developed to tackle these issues, uses an Artificial Intelligence powered, computer vision-based pose estimation algorithm to track patient movements, providing precise performance assessment, immediate feedback, and tailored adjustments. The app operates autonomously, allowing patients to complete sessions without a physical therapist (PT) being present, while a single PT can remotely track progress and monitor dozens of patients offline at their convenience.
This ongoing prospective single-arm international multicenter study spans four continents, testing SmartRehab's feasibility and efficacy for post-stroke motor disability. Participants enrolled receive a 4-week automated telerehabilitation program, prescribed by PTs using the SmartRehab platform. Motor improvements are assessed with the Fugl-Meyer Assessment (FMA) for upper and lower extremities. Usability and satisfaction are measured using the Telehealth Usability Questionnaire (TUQ).
This ongoing multicenter study has enrolled 30 subjects to date, with 15 stroke survivors completing telerehabilitation (mean age 57.6±16.97; 75% male). Preliminary analysis of patients with complete FMA (n=11) revealed a statistically significant improvement in upper extremity motor function (mean change [Baseline-Follow-up: -10.8±6.8; p<0.001]) and a trend toward improvement in lower extremities (mean change: -4.571±4.9; p=0.052). Usability feedback showed high ratings on TUQ (1-poor,7-great, mean 5.87±1.1). Therapists reported high satisfaction, ease of use, and benefits for patients, while adherence rates varied across countries (19%-95%, average 48%), with lower compliance linked to technology challenges
SmartRehab is a feasible and effective telerehabilitation platform for stroke recovery, with high user satisfaction. Significant motor function improvements were observed. Addressing technological barriers may enhance adherence and outcome
Authors/Disclosures
Faddi G. Saleh Velez, MD (University of oklahoma health Sciences center)
PRESENTER 		Dr. Saleh Velez has nothing to disclose.
Elton H. Yeung, MBBS Mr. Yeung has stock in ReMobility Limited. The institution of Mr. Yeung has received research support from World Stroke Organization Future Leader Project. Mr. Yeung has received intellectual property interests from a discovery or technology relating to health care.
Camila Bonin Pinto (Oklahoma University) Camila Bonin Pinto has nothing to disclose.
Tsei Mei Ling (Hong Kong University) No disclosure on file
Matias Alet Matias Alet has nothing to disclose.
Leonardo Carbonera Leonardo Carbonera has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allm. The institution of Leonardo Carbonera has received research support from World Stroke Organization . The institution of Leonardo Carbonera has received research support from Boehringer Ingelheim.
Bogdan Ciopleias, MD Dr. Ciopleias has nothing to disclose.
Abdul Hanif Khan Yusof Khan, MD Prof. Yusof Khan has nothing to disclose.
Zhe Kang Law, MD, PhD Dr. Law has nothing to disclose.
Radhika Lotlikar, MD (Deenanath Mangeshkar Hospital and Research Center) Dr. Lotlikar has nothing to disclose.
Roxanna K. Liu, RN Ms. Liu has nothing to disclose.
Ching Hei So Mr. So has nothing to disclose.
Yin Hei Chan, MBBS Mr. Chan has nothing to disclose.
Gloria C. Poon, MBBS Ms. Poon has nothing to disclose.
Laura Boada Robayo, MD Laura Boada Robayo, MD has nothing to disclose.
Demian Rudyk, MD Dr. Rudyk has nothing to disclose.
Pawel Kiper, PhD Dr. Kiper has nothing to disclose.
Andriy Yabluchanskiy Andriy Yabluchanskiy has nothing to disclose.
Sean I. Savitz, MD Dr. Savitz has nothing to disclose.
Lu LUO Mr. LUO has nothing to disclose.
Wilton W. Fok, PhD Dr. Fok has received personal compensation for serving as an employee of The University of Hong Kong. The institution of Dr. Fok has received research support from Innovation Technology Fund.
Carol Chen, PhD Miss Chen has nothing to disclose.
Wun Yin Lam Mr. Lam has nothing to disclose.
Benny Leung Mr. Leung has nothing to disclose.
Valeria Caso, MD, PhD (Santa Maria Della Misericordia) Dr. Caso has nothing to disclose.
Gustavo Saposnik, MD (Director, Clinical Outcomes & Decision Neuroscience Research Centre) Dr. Saposnik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Saposnik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIHSS. The institution of Dr. Saposnik has received research support from Roche. The institution of Dr. Saposnik has received research support from Heart and Stroke Foundation of Canada.
Gary K. Lau, MBBS (University of Hong Kong) Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Daiichi Sankyo. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Amgen. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Daiichi Sankyo. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Pfizer. Dr. Lau has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Eisai. Dr. Lau has stock in ReMobility. The institution of Dr. Lau has received research support from Croucher Foundation. The institution of Dr. Lau has received research support from Research Fund Secretariat of the Food and Health Bureau, Hong Kong. The institution of Dr. Lau has received research support from Innovation and Technology Bureau, Hong Kong. The institution of Dr. Lau has received research support from Research Grants Council, Hong Kong. Dr. Lau has received publishing royalties from a publication relating to health care.